Perimenopause is a 5–10 year window of increased metabolic vulnerability. GLP-1 addresses visceral adiposity and cardiometabolic risk but doesn't replace estrogen.
What perimenopause changes
Estrogen fluctuations and decline. Increased visceral adiposity. Insulin resistance increase. Sleep disruption. Mood changes. Bone density loss begins.
How GLP-1 helps
Visceral adiposity reduction. Insulin sensitivity improvement. Cardiometabolic risk reduction.
How it doesn't help
Doesn't replace estrogen. Doesn't directly address vasomotor symptoms, mood symptoms, or bone density loss. May add to sleep concerns if GI symptoms disrupt sleep during titration.
Mandatory adjustments
- Higher protein target. 1.8–2.0 g/kg target body weight.
- Resistance training is mandatory. 2–3 sessions/week. Bone-loading exercise specifically.
- Bone density monitoring. Baseline DEXA reasonable; recheck per physician guidance.
- Coordinate with menopause specialist if symptomatic. HRT may be appropriate; not in conflict with GLP-1.
Pregnancy considerations
Perimenopause does not equal infertility. Pregnancy is possible until 12+ months without a period. GLP-1 washout requirements apply if pregnancy is desired.